PMC:6927068 / 1960-3562 JSONTXT

{"project":"0_colil","denotations":[{"id":"31583887-25503845-9139","span":{"begin":650,"end":651},"obj":"25503845"},{"id":"31583887-26784948-9140","span":{"begin":719,"end":720},"obj":"26784948"},{"id":"31583887-26712776-9141","span":{"begin":752,"end":753},"obj":"26712776"},{"id":"31583887-23759756-9142","span":{"begin":832,"end":833},"obj":"23759756"},{"id":"31583887-22883726-9143","span":{"begin":834,"end":835},"obj":"22883726"},{"id":"31583887-16154016-9144","span":{"begin":1094,"end":1095},"obj":"16154016"},{"id":"31583887-20620720-9145","span":{"begin":1096,"end":1097},"obj":"20620720"},{"id":"31583887-21502568-9146","span":{"begin":1600,"end":1602},"obj":"21502568"}],"text":"Hypertension, defined as values ⩾140 mm Hg systolic blood pressure (SBP) and/or ⩾90 mm Hg diastolic blood pressure (DBP), is considered an important and common modifiable risk factor for cardiovascular disease, stroke, renal failure, and death.1 Overall the prevalence of hypertension appears to be around 30–45% of the general population, affecting over one billion people globally, with a steep increase with ageing. The worldwide prevalence of hypertension in individuals aged ⩾25 years was estimated to be approximately 40% in 2008.1 This is equivalent to almost one billion people and is predicted to increase to over 1.5 billion people by 2025.2 The prevalence of hypertension ranges from 24.59% in southern China3 to 36.0% in northeastern China,4 and 59.4% in Chinese patients aged ⩾60 years to 72.8% in those aged ⩾75 years.5,6 The current guidelines confirm that angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), calcium antagonists, beta-blockers, and diuretics are all suitable for the initiation and maintenance of antihypertensive treatment.7,8 However, the prevalence of resistant hypertension, when a therapeutic strategy that includes appropriate lifestyle changes and a diuretic and two other antihypertensive drugs (ADs) belonging to different classes at adequate doses fails to lower SBP and DBP values to \u003c140 and 90 mm Hg respectively, has been reported to range from 5–30% of the overall hypertensive population, and these common ADs may have side effects, including dizziness, fatigue, headache, depressed mood, and sexual dysfunction.9,10"}

{"project":"TEST0","denotations":[{"id":"31583887-231-236-9139","span":{"begin":650,"end":651},"obj":"[\"25503845\"]"},{"id":"31583887-235-240-9140","span":{"begin":719,"end":720},"obj":"[\"26784948\"]"},{"id":"31583887-228-233-9141","span":{"begin":752,"end":753},"obj":"[\"26712776\"]"},{"id":"31583887-229-234-9142","span":{"begin":832,"end":833},"obj":"[\"23759756\"]"},{"id":"31583887-231-236-9143","span":{"begin":834,"end":835},"obj":"[\"22883726\"]"},{"id":"31583887-235-240-9144","span":{"begin":1094,"end":1095},"obj":"[\"16154016\"]"},{"id":"31583887-237-242-9145","span":{"begin":1096,"end":1097},"obj":"[\"20620720\"]"},{"id":"31583887-235-241-9146","span":{"begin":1600,"end":1602},"obj":"[\"21502568\"]"}],"text":"Hypertension, defined as values ⩾140 mm Hg systolic blood pressure (SBP) and/or ⩾90 mm Hg diastolic blood pressure (DBP), is considered an important and common modifiable risk factor for cardiovascular disease, stroke, renal failure, and death.1 Overall the prevalence of hypertension appears to be around 30–45% of the general population, affecting over one billion people globally, with a steep increase with ageing. The worldwide prevalence of hypertension in individuals aged ⩾25 years was estimated to be approximately 40% in 2008.1 This is equivalent to almost one billion people and is predicted to increase to over 1.5 billion people by 2025.2 The prevalence of hypertension ranges from 24.59% in southern China3 to 36.0% in northeastern China,4 and 59.4% in Chinese patients aged ⩾60 years to 72.8% in those aged ⩾75 years.5,6 The current guidelines confirm that angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), calcium antagonists, beta-blockers, and diuretics are all suitable for the initiation and maintenance of antihypertensive treatment.7,8 However, the prevalence of resistant hypertension, when a therapeutic strategy that includes appropriate lifestyle changes and a diuretic and two other antihypertensive drugs (ADs) belonging to different classes at adequate doses fails to lower SBP and DBP values to \u003c140 and 90 mm Hg respectively, has been reported to range from 5–30% of the overall hypertensive population, and these common ADs may have side effects, including dizziness, fatigue, headache, depressed mood, and sexual dysfunction.9,10"}

{"project":"2_test","denotations":[{"id":"31583887-25503845-28906818","span":{"begin":650,"end":651},"obj":"25503845"},{"id":"31583887-26784948-28906819","span":{"begin":719,"end":720},"obj":"26784948"},{"id":"31583887-26712776-28906820","span":{"begin":752,"end":753},"obj":"26712776"},{"id":"31583887-23759756-28906821","span":{"begin":832,"end":833},"obj":"23759756"},{"id":"31583887-22883726-28906822","span":{"begin":834,"end":835},"obj":"22883726"},{"id":"31583887-16154016-28906823","span":{"begin":1094,"end":1095},"obj":"16154016"},{"id":"31583887-20620720-28906824","span":{"begin":1096,"end":1097},"obj":"20620720"},{"id":"31583887-21502568-28906825","span":{"begin":1600,"end":1602},"obj":"21502568"}],"text":"Hypertension, defined as values ⩾140 mm Hg systolic blood pressure (SBP) and/or ⩾90 mm Hg diastolic blood pressure (DBP), is considered an important and common modifiable risk factor for cardiovascular disease, stroke, renal failure, and death.1 Overall the prevalence of hypertension appears to be around 30–45% of the general population, affecting over one billion people globally, with a steep increase with ageing. The worldwide prevalence of hypertension in individuals aged ⩾25 years was estimated to be approximately 40% in 2008.1 This is equivalent to almost one billion people and is predicted to increase to over 1.5 billion people by 2025.2 The prevalence of hypertension ranges from 24.59% in southern China3 to 36.0% in northeastern China,4 and 59.4% in Chinese patients aged ⩾60 years to 72.8% in those aged ⩾75 years.5,6 The current guidelines confirm that angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), calcium antagonists, beta-blockers, and diuretics are all suitable for the initiation and maintenance of antihypertensive treatment.7,8 However, the prevalence of resistant hypertension, when a therapeutic strategy that includes appropriate lifestyle changes and a diuretic and two other antihypertensive drugs (ADs) belonging to different classes at adequate doses fails to lower SBP and DBP values to \u003c140 and 90 mm Hg respectively, has been reported to range from 5–30% of the overall hypertensive population, and these common ADs may have side effects, including dizziness, fatigue, headache, depressed mood, and sexual dysfunction.9,10"}

{"project":"MyTest","denotations":[{"id":"31583887-25503845-28906818","span":{"begin":650,"end":652},"obj":"25503845"},{"id":"31583887-26784948-28906819","span":{"begin":719,"end":721},"obj":"26784948"},{"id":"31583887-26712776-28906820","span":{"begin":752,"end":754},"obj":"26712776"},{"id":"31583887-23759756-28906821","span":{"begin":832,"end":833},"obj":"23759756"},{"id":"31583887-22883726-28906822","span":{"begin":834,"end":836},"obj":"22883726"},{"id":"31583887-16154016-28906823","span":{"begin":1094,"end":1095},"obj":"16154016"},{"id":"31583887-20620720-28906824","span":{"begin":1096,"end":1098},"obj":"20620720"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Hypertension, defined as values ⩾140 mm Hg systolic blood pressure (SBP) and/or ⩾90 mm Hg diastolic blood pressure (DBP), is considered an important and common modifiable risk factor for cardiovascular disease, stroke, renal failure, and death.1 Overall the prevalence of hypertension appears to be around 30–45% of the general population, affecting over one billion people globally, with a steep increase with ageing. The worldwide prevalence of hypertension in individuals aged ⩾25 years was estimated to be approximately 40% in 2008.1 This is equivalent to almost one billion people and is predicted to increase to over 1.5 billion people by 2025.2 The prevalence of hypertension ranges from 24.59% in southern China3 to 36.0% in northeastern China,4 and 59.4% in Chinese patients aged ⩾60 years to 72.8% in those aged ⩾75 years.5,6 The current guidelines confirm that angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), calcium antagonists, beta-blockers, and diuretics are all suitable for the initiation and maintenance of antihypertensive treatment.7,8 However, the prevalence of resistant hypertension, when a therapeutic strategy that includes appropriate lifestyle changes and a diuretic and two other antihypertensive drugs (ADs) belonging to different classes at adequate doses fails to lower SBP and DBP values to \u003c140 and 90 mm Hg respectively, has been reported to range from 5–30% of the overall hypertensive population, and these common ADs may have side effects, including dizziness, fatigue, headache, depressed mood, and sexual dysfunction.9,10"}